A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart ...
Chronic kidney disease affects approximately 850 million people globally, with hyperkalemia representing a disproportionately high burden in this population¹. While hyperkalemia occurs in only 2-3% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results